Aim: To identify factors associated with documented symptomatic and severe hypoglycaemia over 4 years in people with type 2 diabetes starting insulin therapy.
| INTRODUCTION
Good blood glucose control can prevent microvascular complications in people with type 2 diabetes, and there is some evidence that it may prevent or slow the progression of cardiovascular diseases.
1-4 People with type 2 diabetes can often maintain adequate glycaemic control with appropriate lifestyle and oral glucose-lowering drugs (OGLDs), but timely introduction of injection therapy is indicated when glycaemic control is no longer maintained. [5] [6] [7] There is often reluctance, however, to start insulin therapy on the part of both the clinician and the individual with type 2 diabetes because of the need for injections, fear of hypoglycaemia and weight gain and increased complexity of therapy. [8] [9] [10] The Cardiovascular Risk Evaluation in people with type 2 Diabetes on Insulin Therapy (CREDIT) study aimed to evaluate both the relationship between blood glucose control and cardiovascular events prospectively over 4 years in a large cohort of people starting insulin therapy, and to provide insight into routine clinical practice in the management of people with type 2 diabetes using insulin. 11, 12 In an earlier report, we described the evolution of insulin use, associated blood glucose-related outcomes and effects on body weight and hypoglycaemia over the 4 years of the study. 13 In the present study, we aimed to: (1) evaluate the characteristics, both at 1 year and 4 years, that were associated with documented symptomatic hypoglycaemia; (2) understand the nature of those relationships in routine care, particularly for glucose control; (3) discover if those characteristics would apply to severe hypoglycaemia;
and (4) understand how the evolution of insulin regimen (and oral agents) and insulin dose affected hypoglycaemia rates. Previously, we have reported the characteristics of people in the CREDIT study that are associated with weight gain, 14 and those associated with good glycaemic control, 15 and described the relationship between blood glucose control and cardiovascular events. 16 
| MATERIALS AND METHODS
The CREDIT study design, participant selection criteria and participant characteristics have been reported previously. 11, 12 In brief, the study involved 314 centres in 12 countries, 10 in Europe, plus Canada and Japan. Men and women with type 2 diabetes, aged >40 years, who had started any insulin therapy within 12 months and who had a glycated haemoglobin (HbA1c) measurement ≤3 months before beginning insulin were eligible for inclusion. As a noninterventional study, there was no fixed study visit schedule, and insulin choice, dosage, titration, medical costs and concomitant oral agent therapy were according to usual local practice. Ongoing data were gathered prospectively in routine clinical practice, and the treating physicians were asked to report, according to protocol, updated data every 6 months. The results presented here as the 1-and 4-year follow-up data are those provided during the 9 to 18-month and 42 to 54-month windows after starting insulin.
Hypoglycaemia data for the 6 months prior to the annual followup date were collected from patient records and patient recall on structured report forms. Documented symptomatic hypoglycaemia was any non-severe event with clinical symptoms resulting in hypoglycaemia confirmed by self-monitored plasma glucose concentration ≤ 3.9 mmol/L. 17 Severe hypoglycaemia was any event requiring the assistance of another person and confirmed by self-monitored plasma glucose <2.0 mmol/L or prompt recovery after oral carbohydrate, intravenous glucose or intramuscular glucagon. 17 Updated mean HbA1c was the average of HbA1c measurements from 1 month after beginning insulin up to follow-up year values.
Local ethics approval was obtained for all sites, and standards of study conduct were according to the Declaration of Helsinki. Written informed consent was obtained from all participants in advance.
A statistical analysis plan was developed prior to data analysis.
The principal outcome measure was the occurrence of documented symptomatic hypoglycaemia in any participant over the 6 months before the year 1 and year 4 follow-up visits. 3 | RESULTS
| Glucose control and insulin regimens
Detailed core study results of glucose control and changes in insulin regimen are given elsewhere. 13 Basal insulin and mealtime insulin usage declined over the 4 years, use of basal plus mealtime insulin increased and premixed insulin usage remained relatively constant. Table S1 .
| Hypoglycaemia incidence and event rates
A total of 2729 and 2271 people had data on hypoglycaemia during the last 6 months of years 1 and 4 of follow-up, respectively. The proportions of participants (incidence) with documented symptomatic hypoglycaemia in the 6 months before the year 1 and 4 follow-up visits, respectively, were: 15.0% and 14.9% for those on basal insulin; Table 1 ).
The event rate for severe hypoglycaemia was less certain, with a range of 0.03 to 0.08 events/person in the 6-month period anytime, and 0.01 to 0.02 events/person in the 6-month period at night ( Table 1 ).
The rate of documented symptomatic hypoglycaemia was greater for those who achieved updated mean HbA1c <7.0% (<53 mmol/mol) 
| Predictors and explanatory factors for hypoglycaemia
Univariate analysis identified 9 variables when starting insulin and 9 variables at year 1 that were associated with documented symptomatic hypoglycaemia at year 1 ( Table 2 ). The number of variables associated with documented symptomatic hypoglycaemia at year 4 was 8 when starting insulin and 5 at year 4 (Table 3) . Baseline variables that were found in common in years 1 and 4 were body weight, BMI and physical activity. Variables in common at both visit years were change in body weight, mean HbA1c (from 6 months before to 1 month after nominal visit date), change in HbA1c and insulin regimen. 
| DISCUSSION
This analysis of hypoglycaemia and its associations contributes data of clinical interest in 4 main areas, all derived from a large multinational non-interventional cohort followed for 4 years after starting insulin and collected pragmatically from usual clinical care.
We describe the incidence of hypoglycaemia, predictors and in-study explanatory factors for such events, their relationship to the trajectory of HbA1c and relationship with insulin regimen. We have previously described the evolution of individually chosen insulin regimens and their relation to glucose control, 13 together with analyses of predictors of weight change, glucose control and a description of the relationship of the latter to cardiovascular events.
14-16
The pragmatic, real-life study design may have a limitation with regard to data acquisition, as hypoglycaemia is poorly identified and recorded in usual clinical practice; however, this may mean that our analysis is focused on events more important to people with diabetes, and thus not forgotten. Accordingly we limited data collection to the 6 months before the annual clinical visits, a period similar to the 26 weeks often used in phase III clinical studies. In this context, 6-month incidence (proportion of people affected) was not high at~16% to 19%, and with no evidence of deterioration of rate over 4 years (numerically a decrease), in contrast to what might have been expected with the move to more complex insulin regimens and with increased duration of diabetes. 13 An explanation for this may be that individuals were actively managed to avoid hypoglycaemia; certainly, there was considerable change in individual insulin regimen. 13 The incidence results are consistent with reviews of studies on starting insulin (17% over 6 months
18
) and the ORIGIN study (28% over 6 years 19 ), but both those studies used lower glucose thresholds and would thus be expected to give somewhat lower rates. Our findings are higher than in those of some registry studies which may identify only more severe episodes, 20, 21 and much lower than the extraordinarily high rates in another study where daily recording might have led to a positive ascertainment bias. 22 Severe hypoglycaemia was~2% overall in 6 months, again did not deteriorate in incidence over 4 years, and again matches or contrasts with results from the studies just referenced.
Event rates for documented symptomatic hypoglycaemia were~1.0 per 6 months (Table 1) The relationship of hypoglycaemia to achieved glucose control is controversial, notably after the identification in the ACCORD intensive arm of higher severe hypoglycaemia rates in those at higher HbA1c levels. 25 Many studies did not find any relationship, 20, 26 although the ORIGIN study (for documented symptomatic hypoglycaemia) 19 and the review by Karl et al 18 found more hypoglycaemia at lower attained HbA1c. There was also no relationship with current HbA1c in the standard control group in ACCORD, with a similar HbA1c to our own findings. 25 In the present study, we found lower attained HbA1c and higher change from baseline in HbA1c to be significant univariate associations with documented symptomatic hypoglycaemia. At year 1 this effect was retained on multivariate analysis, with odds of 25% per %-unit of HbA1c. At year 4, updated current HbA1c was also retained as a risk factor, with the OR having a non-linear relationship to HbA1c, but such that at around an HbA1c of 7.5% (58 mmol/mol) the OR was falling 10% to 20% per %-unit. These findings and the literature can probably be reconciled. When titration is forced as in the ACCORD study, it seems vulnerable people with other medical conditions become stuck at higher levels of HbA1c with excess rates of hypoglycaemia. In more normal care, hypoglycaemia may determine attained HbA1c level ("treat-to-hypoglycaemia"), and in these circumstances hypoglycaemia rates may eventually become the same at all levels of HbA1c. The study population in CREDIT, however, appears to have been more actively managed, judged by the extensive changes to insulin regimens and increasing insulin doses, 13 and then people managed more closely to normal levels will be at higher risk of hypoglycaemia. This may affect in particular regimens containing mealtime insulin, with selective moves away from basal + mealtime and premixed regimens accounting for the reduction in odds ratios compared with basal between years 1 and 4, indeed becoming non-statistically significant.
Lastly, dose on starting insulin was still a significant factor at year 1, as was actual insulin dose at the time, and the latter was retained as an independent factor on multivariable analyses, when the ORs suggest an increase of~10% in risk per 0.1 U/kg/d dose difference.
This decreased to~5% at 4 years in model 2 and was not retained in model 3, and would again appear to suggest the issue was mitigated over time with appropriate clinical management.
For severe hypoglycaemia, we recognized that our data would be too sparse in people with type 2 diabetes to perform the same associative analyses, with inevitable overfitting and model optimism. We therefore examined whether the models developed from the whole dataset would perform adequately when populated with the severe hypoglycaemia data alone. This proved true of all the models devel- to reduce documented symptomatic hypoglycaemia should reduce severe hypoglycaemia, consistent with the DEVOTE study findings. 27 As noted above, the present study has limitations related to ascertainment, although with the incidence data matching other studies 18,19 the problem is much smaller than found in database studies.
Non-database studies do, however, inevitably involve some patient selection, consequent on-site selection. As we note above this population appears to be relatively actively managed, although not as intensively as treat-to-target or intensive therapy studies, and the findings may not be generalizable to situations where insulin therapy is less optimally managed. Furthermore, the motivators of clinical decision-making for each individual were not recorded (or indeed easy to record), so how hypoglycaemia rates were stopped from rising with increasing duration of diabetes and higher insulin doses over 4 years is unclear. Methodologically, we did define candidate variables for correlation (univariate) analysis in order to reduce risks from over-fitting, and although these included all those variables known from the literature (and others), it remains possible some factor of significance was missing. Furthermore some variables of potential interest, such as non-cardiovascular morbidities and social functioning, 24, 28 were not included nor collected for our analysis.
In conclusion, documented and severe hypoglycaemia occurred at significant but not high rates in people with type 2 diabetes who Variables retained on multivariable analysis: linear variables that influence documented symptomatic hypoglycaemia at (A) year 1 and (B) year 4, and non-linear variables that influence documented symptomatic hypoglycaemia at year 4 -cubic spline results for (C) glycated haemoglobin (HbA1c) and (D) baseline diastolic blood pressure -in people with type 2 diabetes. *P value is for oral glucose-lowering drugs (OGLDs) in 3 classes: no sulphonylurea (SU), SU, no OGLD. P values for C and D were P = .0208 and .0032, respectively. BP, blood pressure; CI, confidence interval
